Nivolumab 是PD-1抗体类抑制剂，可用于研究晚期（转移性）非小细胞肺癌。

Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineoplastic activities.

946414-94-4

146 kDa